Upon comparison of the frequency of M. tuberculosis–specific CD4+ T cells between the current cohort and the 2018 prepandemic cohort with LTBI, we found that the magnitude of M. tuberculosis–specific CD4+ T cells was approximately 5-fold lower in the HIV-uninfected COVID-19 group and approximately 2-fold lower in the HIV-infected COVID-19 group compared with prepandemic samples (medians: 0.17% vs. 0.53% for HIV–, P < 0.0001 and 0.09% vs. 0.17% for HIV+, P = 0.052, respectively). Here, CD4 is linked to COVID-19.